Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Petrelintide

Petrelintide

Amylin · s.c. · Zealand / Roche

Data cut 12 November 2026 · page built 16 November 2026 · 6 trial arms · 2 trials with results · 4 registered trials · see on the pipeline board

Summary

Also known as
ZP8396
Mechanism
Amylin
Route
s.c.
Company
Zealand / Roche
Highest development stage
phase 3
Status (as of data cut)
Phase 3 ZUPREME programme (ZUPREME-3, -4, -5) initiated with Roche; phase 2 ZUPREME-1 published (Lancet Diabetes Endocrinol 2026), ZUPREME-2 topline in T2D (Oct 2026) verify
Next milestone
Phase 3 readouts

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 3 ongoing
T2D2 phase 3 ongoingPhase 3 ongoing
CV outcomes2 phase 3 ongoingPhase 3 ongoing
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
ZUPREME-1petrelintide 1.0 mgobesity28—−7.9 % vs −1.7 %
Δ −6.2 pp
——5.0 vs 5.016.5 vs 24.719.0 vs 6.04.0 vs 6.03.0 vs 4.0—verified
ZUPREME-1petrelintide 2.5 mgobesity28—−7.9 % vs −1.7 %
Δ −6.2 pp
——1.0 vs 5.011.1 vs 24.712.0 vs 6.00.0 vs 6.01.0 vs 4.0—verified
ZUPREME-1petrelintide 5.0 mgobesity28—−9.8 % vs −1.7 %
Δ −8.1 pp
——5.0 vs 5.09.6 vs 24.723.0 vs 6.00.0 vs 6.06.0 vs 4.0—verified
ZUPREME-1petrelintide 7.0 mgobesity28—−9.3 % vs −1.7 %
Δ −7.6 pp
——1.0 vs 5.012.7 vs 24.715.0 vs 6.03.0 vs 6.04.0 vs 4.0—verified
ZUPREME-1petrelintide 9.0 mgobesity28—−9.4 % vs −1.7 %
Δ −7.7 pp
——10.0 vs 5.018.3 vs 24.728.0 vs 6.09.0 vs 6.04.0 vs 4.0—verified
ZUPREME-2 (obesity + T2D)petrelintide, highest doset2d28—−9.2 % vs −2.0 %
Δ −7.2 pp
—−0.7 vs +0.2——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (32)
  • petrelintide 1.0 mg · weight_eff · Abstract; Table 2
    −7·9% (95% CI −9·0 to −6·7) with petrelintide 1·0 mg
  • petrelintide 1.0 mg · ae_dc · Table 3
    Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
  • petrelintide 1.0 mg · nausea · Table 3
    Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
  • petrelintide 1.0 mg · vomiting · Table 3
    Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
  • petrelintide 1.0 mg · sae · Table 3
    Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
  • petrelintide 1.0 mg · disc_any · Figure 1 (trial profile)
    13 discontinued treatment 4 adverse events
  • petrelintide 2.5 mg · weight_eff · Abstract; Table 2
    −7·9% (−9·0 to −6·7) with petrelintide 2·5 mg
  • petrelintide 2.5 mg · ae_dc · Table 3
    Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
  • petrelintide 2.5 mg · nausea · Table 3
    Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
  • petrelintide 2.5 mg · vomiting · Table 3
    Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
  • petrelintide 2.5 mg · sae · Table 3
    Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
  • petrelintide 2.5 mg · disc_any · Figure 1 (trial profile)
    9 discontinued treatment 4 lack of efficacy 4 other 1 adverse event
  • petrelintide 5.0 mg · weight_eff · Abstract; Table 2
    −9·8% (−10·9 to −8·6) with petrelintide 5·0 mg
  • petrelintide 5.0 mg · ae_dc · Table 3
    Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
  • petrelintide 5.0 mg · nausea · Table 3
    Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
  • petrelintide 5.0 mg · vomiting · Table 3
    Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
  • petrelintide 5.0 mg · sae · Table 3
    Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
  • petrelintide 5.0 mg · disc_any · Figure 1 (trial profile)
    8 discontinued treatment 4 adverse events
  • petrelintide 7.0 mg · weight_eff · Abstract; Table 2
    −9·3% (−10·5 to −8·2) with petrelintide 7·0 mg
  • petrelintide 7.0 mg · ae_dc · Table 3
    Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
  • petrelintide 7.0 mg · nausea · Table 3
    Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
  • petrelintide 7.0 mg · vomiting · Table 3
    Vomiting 3 (4%) 0 0 2 (3%) 7 (9%) 12 (3%) 5 (6%)
  • petrelintide 7.0 mg · sae · Table 3
    Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
  • petrelintide 7.0 mg · disc_any · Figure 1 (trial profile)
    10 discontinued treatment 7 other 1 adverse event
  • petrelintide 9.0 mg · weight_eff · Abstract; Table 2
    −9·4% (−10·5 to −8·3) with petrelintide 9·0 mg
  • petrelintide 9.0 mg · ae_dc · Table 3
    Adverse events leading to discontinuation of treatment* 4 (5%) 1 (1%) 4 (5%) 1 (1%) 8 (10%) 16 (4%) 4 (5%)
  • petrelintide 9.0 mg · nausea · Table 3
    Nausea 15 (19%) 10 (12%) 19 (23%) 12 (15%) 23 (28%) 79 (20%) 5 (6%)
  • petrelintide 9.0 mg · vomiting · Results, paragraph 10; Table 3
    The petrelintide 9·0 mg group was the only group in which the incidence of vomiting (seven [9%] of 82) exceeded that observed with placebo
  • petrelintide 9.0 mg · sae · Table 3
    Serious adverse events 2 (3%) 1 (1%) 5 (6%) 3 (4%) 3 (4%) 14 (3%) 3 (4%)
  • petrelintide 9.0 mg · disc_any · Figure 1 (trial profile)
    15 discontinued treatment 8 adverse events
  • petrelintide, highest dose · weight_eff · company announcement
    Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo
  • petrelintide, highest dose · hba1c · company announcement
    At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with placebo

Registered trials (4)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
ZUPREME-4
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
ObesityPhase 3recruiting2026-10 → 2028-10600recruitingNCT07843485
ZUPREME-5
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease
ObesityPhase 3recruiting2026-09 → 2030-072500recruitingNCT07843472
ZUPREME-3
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
ObesityPhase 3recruiting2026-09 → 2028-123900recruitingNCT07843498
NCT06951854
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
OtherPhase 2recruiting2025-04 → 2025-09105recruitingNCT06951854

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Petrelintide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/petrelintide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.